12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effects of HDV infection and pegylated interferon α treatment on the natural killer cell compartment in chronically infected individuals.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although hepatitis delta is considered an immune-mediated disease, adaptive immune responses to hepatitis delta virus (HDV) are hardly detectable. Thus, the role of other immune responses, including those mediated by natural killer (NK) cells, must be considered in HDV pathogenesis and in treatments with immune-stimulating agents such as interferon (IFN)α. However, the phenotype and function of NK cells in chronic HDV infection, or in HDV-infected individuals undergoing IFNα treatment, have not been extensively studied.

          Related collections

          Author and article information

          Journal
          Gut
          Gut
          1468-3288
          0017-5749
          Mar 2015
          : 64
          : 3
          Affiliations
          [1 ] Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.
          [2 ] Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden.
          [3 ] Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden Institute for Cancer Research, Oslo University Hospital, Oslo, Norway Institute for Cancer Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
          [4 ] Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden Liver Immunology Laboratory, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
          Article
          gutjnl-2014-306767
          10.1136/gutjnl-2014-306767
          24721903
          85ba6aa1-d675-4e69-b853-cecfdb1f1d44
          Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
          History

          Hepatitis D,Immunology,Interferon-Alpha
          Hepatitis D, Immunology, Interferon-Alpha

          Comments

          Comment on this article